Fiche centre
Institut Paoli Calmettes
Marseille — France
Essais liés5clinical trials
VilleMarseillelocalisation
PaysFrancelocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06211764
Essais cliniques associés
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| RCHOP21 | SEP | Phase 3 | NCT01285765 | Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients | COMPLETED |
| TAR-200 | Cancer | Phase 3 | NCT06211764 | SunRISe-5 — A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) | ACTIVE_NOT_RECRUITING |
| Fludarabine, Busulfan, Thymoglobuline | Cancer | Phase 2 | NCT00841724 | ITT 08-01 — Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies | COMPLETED |
| Tacabrutideg | Cancer | Phase 1/2 | NCT05006716 | CaDAnCe-101 — A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | RECRUITING |
| Sacituzumab govitecan-hziy | Cancer | Phase 3 | NCT06486441 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) | ACTIVE_NOT_RECRUITING |